$ENTA
ENANTA PHARMACEUTICALS INC

2022 Q1 Form 10-Q Financial Statement

#000095017022008483 Filed on May 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $18.72M $20.13M
YoY Change -7.03% -27.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.48M $8.330M
YoY Change 25.76% 21.08%
% of Gross Profit
Research & Development $42.09M $41.51M
YoY Change 1.4% 27.28%
% of Gross Profit
Depreciation & Amortization $822.0K $840.0K
YoY Change -2.14% -8.7%
% of Gross Profit
Operating Expenses $42.09M $41.51M
YoY Change 1.4% 27.28%
Operating Profit -$33.85M -$29.70M
YoY Change 13.96% 150.11%
Interest Expense $255.0K $550.0K
YoY Change -53.64% -71.79%
% of Operating Profit
Other Income/Expense, Net $255.0K $545.0K
YoY Change -53.21% -72.05%
Pretax Income -$33.59M -$29.16M
YoY Change 15.22% 193.75%
Income Tax $0.00 $7.110M
% Of Pretax Income
Net Earnings -$33.59M -$22.05M
YoY Change 52.38% 267.11%
Net Earnings / Revenue -179.48% -109.5%
Basic Earnings Per Share -$1.63 -$1.09
Diluted Earnings Per Share -$1.63 -$1.09
COMMON SHARES
Basic Shares Outstanding 20.55M 20.17M
Diluted Shares Outstanding 20.55M 20.17M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $280.3M $375.9M
YoY Change -25.43% 5.8%
Cash & Equivalents $40.99M $77.73M
Short-Term Investments $239.3M $298.8M
Other Short-Term Assets $14.08M $32.10M
YoY Change -56.14% 62.12%
Inventory
Prepaid Expenses
Receivables $18.72M $20.10M
Other Receivables $28.75M $0.00
Total Short-Term Assets $341.9M $428.2M
YoY Change -20.16% 6.33%
LONG-TERM ASSETS
Property, Plant & Equipment $4.815M $14.00M
YoY Change -65.61% -20.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $42.22M $24.50M
YoY Change 72.32% -69.41%
Other Assets $92.00K $1.000M
YoY Change -90.8% -92.37%
Total Long-Term Assets $64.95M $39.60M
YoY Change 64.01% -64.26%
TOTAL ASSETS
Total Short-Term Assets $341.9M $428.2M
Total Long-Term Assets $64.95M $39.60M
Total Assets $406.8M $467.8M
YoY Change -13.04% -8.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.985M $5.700M
YoY Change 5.0% -3.39%
Accrued Expenses $21.74M $15.74M
YoY Change 38.08% 60.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.74M $26.60M
YoY Change 15.56% 36.41%
LONG-TERM LIABILITIES
Long-Term Debt $1.506M $1.500M
YoY Change 0.4% -6.25%
Other Long-Term Liabilities $876.0K $994.0K
YoY Change -11.87% -4.05%
Total Long-Term Liabilities $876.0K $994.0K
YoY Change -11.87% -4.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.74M $26.60M
Total Long-Term Liabilities $876.0K $994.0K
Total Liabilities $48.24M $31.70M
YoY Change 52.16% 15.27%
SHAREHOLDERS EQUITY
Retained Earnings -$15.13M
YoY Change
Common Stock $376.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $358.6M $436.0M
YoY Change
Total Liabilities & Shareholders Equity $406.8M $467.8M
YoY Change -13.04% -8.9%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$33.59M -$22.05M
YoY Change 52.38% 267.11%
Depreciation, Depletion And Amortization $822.0K $840.0K
YoY Change -2.14% -8.7%
Cash From Operating Activities -$26.38M -$4.580M
YoY Change 475.87% -131.2%
INVESTING ACTIVITIES
Capital Expenditures -$74.00K -$130.0K
YoY Change -43.08% -62.86%
Acquisitions
YoY Change
Other Investing Activities -$34.98M $25.59M
YoY Change -236.7% -8.93%
Cash From Investing Activities -$35.06M $25.46M
YoY Change -237.69% -8.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.351M 1.150M
YoY Change 191.39% -73.56%
NET CHANGE
Cash From Operating Activities -26.38M -4.580M
Cash From Investing Activities -35.06M 25.46M
Cash From Financing Activities 3.351M 1.150M
Net Change In Cash -58.08M 22.03M
YoY Change -363.64% -52.91%
FREE CASH FLOW
Cash From Operating Activities -$26.38M -$4.580M
Capital Expenditures -$74.00K -$130.0K
Free Cash Flow -$26.30M -$4.450M
YoY Change 491.03% -129.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#RoyaltyMember
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#RoyaltyMember
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001177648
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#RoyaltyMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#RoyaltyMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#RoyaltyMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35839
dei Entity Registrant Name
EntityRegistrantName
ENANTA PHARMACEUTICALS, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3205099
dei Entity Address Address Line1
EntityAddressAddressLine1
500 Arsenal Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
607-0800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
ENTA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20712691
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40989000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57206000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
239338000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
186796000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18716000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23576000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14078000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14188000
CY2022Q1 us-gaap Income Tax Receivable
IncomeTaxReceivable
28748000
CY2021Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
37255000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
341869000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
108416000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4815000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5943000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
319021000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
42218000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17216000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4711000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
608000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
92000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
92000
CY2022Q1 us-gaap Assets
Assets
406818000
CY2021Q3 us-gaap Assets
Assets
438791000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5985000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9540000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21740000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22429000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3013000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4203000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
30738000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
36172000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15115000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1126000
CY2022Q1 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1506000
CY2021Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1506000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
876000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
558000
CY2022Q1 us-gaap Liabilities
Liabilities
48235000
CY2021Q3 us-gaap Liabilities
Liabilities
39362000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20618000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20618000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20238000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20238000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
206000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
202000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
376545000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
351033000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3037000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-382000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15131000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
48576000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
358583000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
399429000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
406818000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
438791000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18716000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20132000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46364000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51875000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
52563000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
49832000
us-gaap Costs And Expenses
CostsAndExpenses
110620000
us-gaap Costs And Expenses
CostsAndExpenses
93874000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-33847000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42087000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41506000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90636000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78171000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10476000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8326000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19984000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15703000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-29700000
us-gaap Operating Income Loss
OperatingIncomeLoss
-64256000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41999000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
255000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
545000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
549000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1222000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
255000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
545000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
549000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1222000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33592000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29155000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63707000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40777000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7110000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10404000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33592000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-22045000
us-gaap Net Income Loss
NetIncomeLoss
-63707000
us-gaap Net Income Loss
NetIncomeLoss
-30373000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.63
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.63
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20551000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20171000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2655000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20171000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20473000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2031000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-350000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20473000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20131000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20551000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20131000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33592000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-22045000
us-gaap Net Income Loss
NetIncomeLoss
-63707000
us-gaap Net Income Loss
NetIncomeLoss
-30373000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-789000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2031000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-350000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2655000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-789000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35623000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22395000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66362000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31162000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
455580000
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
833000
CY2020Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-534000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4883000
CY2020Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-439000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-8328000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
451995000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1152000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5280000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-350000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-22045000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
436032000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
399429000
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10409000
CY2021Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-777000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6062000
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-624000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-30115000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
384384000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3802000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-451000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6471000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2031000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33592000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
358583000
us-gaap Profit Loss
ProfitLoss
-63707000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5444000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1703000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-8507000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-0
enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-2784000
enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-2565000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3473000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
15000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-808000
us-gaap Profit Loss
ProfitLoss
-30373000
us-gaap Share Based Compensation
ShareBasedCompensation
12533000
us-gaap Share Based Compensation
ShareBasedCompensation
10163000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1602000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1705000
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
802000
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
1238000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-928000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-956000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4860000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3360000
enta Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2498000
enta Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2797000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
318000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-84000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39646000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19469000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
124631000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
171586000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
135514000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
179917000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
437000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
318000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10446000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8013000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14211000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1985000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1228000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
534000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12983000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1451000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16217000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10005000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57814000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87739000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41597000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
77734000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
174000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
17000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15559000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2517000
us-gaap Year Founded
YearFounded
1995
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, management’s judgments with respect to its revenue arrangements; valuation of stock-based awards and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The future developments of the COVID-19 pandemic also may directly or indirectly impact the Company’s business. The Company has made estimates of the impact of COVID-19 in the Company’s consolidated financial statements as of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Actual results could differ from the Company’s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
317912000
CY2022Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1506000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
350031000
CY2021Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1506000
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
284209000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2659000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
281556000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
295210000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
96000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
94000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
295212000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
42218000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
108416000
CY2022Q1 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
14412000
CY2021Q3 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
8402000
CY2022Q1 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
2616000
CY2021Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
6062000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2960000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6094000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
633000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
700000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1119000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1171000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21740000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22429000
CY2022Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
530000
CY2021Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
558000
CY2022Q1 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
346000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
876000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
558000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3852000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10163000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5280000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12533000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
82997000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2496000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
47.87
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M12D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
63476000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.61
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M24D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
49173000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
713000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
73.82
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
345000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
41.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
96000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
67.91
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4124000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
53.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
82997000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4124000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
53.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6471000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5280000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12533000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10163000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6471000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.11
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
66162000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33592000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-22045000
us-gaap Net Income Loss
NetIncomeLoss
-63707000
us-gaap Net Income Loss
NetIncomeLoss
-30373000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20551000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20171000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20473000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20131000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33592000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-22045000
us-gaap Net Income Loss
NetIncomeLoss
-63707000
us-gaap Net Income Loss
NetIncomeLoss
-30373000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20551000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20171000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20473000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20131000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20551000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20171000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20473000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20131000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.63
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3699000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4268000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3267000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4307000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7110000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10404000
CY2022Q1 us-gaap Income Tax Receivable
IncomeTaxReceivable
28748000
CY2021Q4 enta Increase Decrease In Right Of Use Asset And Lease Liability
IncreaseDecreaseInRightOfUseAssetAndLeaseLiability
15048000

Files In Submission

Name View Source Status
0000950170-22-008483-index-headers.html Edgar Link pending
0000950170-22-008483-index.html Edgar Link pending
0000950170-22-008483.txt Edgar Link pending
0000950170-22-008483-xbrl.zip Edgar Link pending
enta-20220331.htm Edgar Link pending
enta-20220331.xsd Edgar Link pending
enta-20220331_cal.xml Edgar Link unprocessable
enta-20220331_def.xml Edgar Link unprocessable
enta-20220331_htm.xml Edgar Link completed
enta-20220331_lab.xml Edgar Link unprocessable
enta-20220331_pre.xml Edgar Link unprocessable
enta-ex10_1.htm Edgar Link pending
enta-ex31_1.htm Edgar Link pending
enta-ex31_2.htm Edgar Link pending
enta-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img215112886_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending